Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Isaac Yang

Brain & Spinal Tumor · UCLA

View

Dr. Philip Schauer

Bariatric Surgery · PBRC

View

Dr. Justin Hovey, FAAP, FACP, DABOM

Obesity Medicine · Noland Hospital Dothan II

View

Dr. Kimberly Gudzune

Obesity Medicine · JHU

View

Dr. Richard Dutton

General Anesthesiology · UMSOM

View

Dr. Sarah Ro

Obesity Medicine · UNC Health Care

View

Dr. Rebecca Andrews

Primary Care · UCHC

View

Dr. Jed Wolpaw

General Anesthesiology · Johns Hopkins

View

Dr. Matt Sherrer

Perioperative Med · UAB

View

Dr. David Bates

General Internal Medicine · BWH

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Clinical Utility of [18F]-Fluciclovine PET/MRI for Differentiating True Progression from Treatment-Related Changes in Patients with Glioblastoma.

    Jun 3, 2026DOI: 10.3174/ajnr.a9120Journal ArticleAJNR

    Written by: Jana IvanidzeKellen Vo VuRongwei FuAndrew BrandmaierLaszlo SzidonyaGagandeep ChoudharyJay StarkeyTony J WangMichael SistiL Guy McKhannSushant PuriMarcus KonnerMichelle RoytmanEaton LinAndrew KuhnJoseph R OsbornePhilip E StiegKathryn BealRohan R RamakrishnaGagandeep SinghAngela Lignelli-DippleMikhail DoubrovinAnh Huan VoMary WelchFabio IwamotoAya HaggiagiLaura DonovanMaria Diaz OrdonezBrian GillBenjamin LiechtyDavid J PisapiaJosh WalkerRajiv S MaggeMatthew WoodValentina Marulanda CorzoOlabisi R SanusiAhmed RaslanAclan DoganStephen BowdenSadek A NehmehJoshua NickersonNadine MallakAmber RuizPrakash AmbadyAli NabavizadehRamon F Barajas

    Find these authors on Roon

    RR
    Dr. Rohan Ramakrishna
    Brain & Spinal Tumor · WCM

    INTRODUCTION

    Glioblastoma (GBM, Isocitrate Dehydrogenase [IDH] wild type, World Health Organization [WHO] Grade 4 Astrocytoma) is the most aggressive primary brain malignancy in adults, characterized by rapid proliferation, diffuse infiltration, and poor prognosis despite maximal resection combined with subsequent Stupp protocol temozolomide based chemoradiotherapy (CRT) 1. Gadolinium-based contrast enhanced MRI (Gd-MRI) remains the standard-of-care for response assessment but lacks biological specificity, as both tumor growth (true progression) and treatment-related inflammatory changes disrupt the blood-brain-barrier and produce similar enhancement patterns. Consequently, accurately distinguishing true progression from treatment-related change remains difficult and may lead to premature therapy discontinuation, delayed switching to second-line regimens, or unnecessary surgical interventions. Despite efforts to improve standardization, current response assessment criteria such as RANO 2.0 remains limited by its reliance on longitudinal characterization of nonspecific Gd-MRI features. As such, there is a critical need for biologically specific imaging biomarkers that improve upon the accuracy of Gd-MRI for GBM response assessment.Physiology-based imaging approaches, including perfusion MRI and amino acid PET imaging, have emerged to address limitations of Gd-MRI. Dynamic susceptibility contrast (DSC) perfusion MRI derived cerebral blood volume (CBV) is commonly used in the clinical assessment of GBM due to its ability to detect microvascular proliferation, however the effects of CRT can confound interpretation. A meta-analysis reported pooled sensitivity of 0.84 and specificity of 0.78 for identifying GBM progression, with results limited by inter-institutional protocol variability and susceptibility artifacts. 2 Dynamic contrast-enhanced (DCE) perfusion MRI represents a robust approach to assess intravascular volume (VP) and blood brain barrier permeability (Ktrans) and has been shown to be a helpful adjunct modality in assessment of GBM in the post treatment setting. While it is not affected by susceptibility artifact, DCE-MRI is affected by variability in institutional protocols similar to DSC-MRI.Compared to perfusion MRI, amino acid PET imaging provides a more direct and biologically specific measure of lesional metabolic activity through assessment of amino acid transport3. Various amino acid PET radiotracers, including [F18]FET, [F18]FDOPA, and [C11]MET, have been developed and studied in the context of GBM response assessment. These radiotracers offer biological specificity and improved diagnostic accuracy for distinguishing true progression from treatment-related changes in GBM. 3–6 The most recent RANO/EANO consensus guidelines highlight its clinical utility in diagnosis, RT planning, and response assessment3,4,7. Amino acid PET has shown clinical utility and cost-effectiveness in a variety of neuro-oncologic settings8,9, and is increasingly being adopted in Europe. 10
    Trans-1-amino-3-[F18]-fluorocyclobutane-1-carboxylic acid ([F18]-FACBC, also known as [F18]-Fluciclovine), is the only FDA-approved amino acid PET tracer currently available in the United States. Originally developed and approved for evaluating recurrent prostate cancer, [F18]-Fluciclovine has an excellent safety profile, and targets the ASCT2 and LAT1 transporters5. In recent years, [F18]-Fluciclovine has gained attention in the field of neuro-oncology as ASCT2 and LAT1 are overexpressed in GBM and other high-grade gliomas, as well as in brain metastases. 11 In a recent prospective study by Nabavizadeh et al., [F18]-Fluciclovine PET/MRI SUVmax cutoff threshold value of 4.66 demonstrated high diagnostic accuracy of 90% sensitivity and 83% specificity for distinguishing tumor progression from treatment effects, with an area under the curve (AUC) value of 0.8612. However, broader clinical adoption of [F18]-Fluciclovine PET in neuro-oncology has been hindered by a paucity of real-world, multi-center data supporting its diagnostic performance in routine clinical settings. The scientific premise of this study is that [F18]-Fluciclovine PET/MRI, when applied in routine clinical practice, retains high diagnostic accuracy and reproducibility for identifying true progression in patients with GBM who present with new or enlarging contrast enhancement in the post-treatment setting. Therefore, we hypothesize that [F18]-Fluciclovine PET/MRI absolute SUVmax measurements obtained in standard clinical workflows can reliably differentiate true tumor progression from treatment-related changes and serve as a valuable adjunct to Gd-MRI.
    The purpose of this retrospective, two-institution study was to evaluate the clinical real-world performance of [F18]-Fluciclovine PET/MRI in differentiating tumor progression from treatment-related changes in patients with radiographically suspected (presumed) GBM progression. We demonstrate that [F18]-Fluciclovine SUVmax provides high diagnostic accuracy across institutions, reinforcing its potential role as a biologically targeted imaging biomarker in patients with GBM.

    MATERIALS AND METHODS

    This retrospective study was conducted under institutional review board approved protocols at Institution 1 (Oregon Health & Science University) and Institution 2 (Weill Cornell Medicine). Informed consent was waived due to the retrospective nature of the study. We performed a multi-institutional cohort study to evaluate the clinical utility of [F18]-Fluciclovine PET/MRI in distinguishing true progression from treatment-related effects in patients with GBM (defined according to the World Health Organization 2021 classification) who previously received standard-of-care maximal safe resection followed by Stupp protocol radiation and concurrent temozolomide chemotherapy and adjuvant temozolomide. 1 Prior to undergoing [F18]-Fluciclovine PET/MRI, some patients were treated with bevacizumab for steroid-sparing management of cerebral edema or for treatment of a prior episode of disease progression. All patients underwent clinically indicated [F18]-Fluciclovine PET/MRI per institutional protocol, at the time of presumed disease progression as assessed by Gd-MRI RANO 2.0 (new contrast-enhancing lesions or lesions showing a ≥25% increase in the sum of the products of the perpendicular diameters). All patients subsequently underwent maximal safe resection of the developing enhancing lesion or longitudinal Gd-MRI and clinical follow-up to define disease status. A STARD checklist is provided as Supplementary Table 1. 13
    [F18]-Fluciclovine radiotracer was acquired from commercial radiopharmaceutical vendors. All patients fasted for at least 4 hours prior to tracer administration. 185 ± 19 MBq (5 ± 0.5 mCi) at Institution 1 or 370 ± 37 MBq (10 ± 1.0 mCi) at Institution 2 of [F18]-Fluciclovine were administered intravenously. Imaging was performed using integrated PET/MRI systems: a GE SIGNA PET/MRI system (Institution 1 and Institution 2) or a Siemens Biograph mMR (Institution 2). At Institution 1, 3D-list mode PET acquisition was performed starting at injection for 60 minutes, and summed images were reconstructed from 40-50 minutes from injection and sent to PACS for clinical interpretation. At Institution 2, PET acquisition was performed in 3D-list mode from 30-50 minutes post-injection, and the 20-minute dataset was reconstructed and sent to PACS for clinical interpretation. At both institutions, standard iterative reconstruction algorithms with atlas- or Zero-Echo Time image-based attenuation correction were applied.
    Brain MRI without and with gadolinium-based contrast was performed concurrently with the PET/MRI or within 2 weeks of the PET/MRI using institutional clinical brain tumor imaging protocols. Brain Tumor Imaging Protocol sequences included pre- and postcontrast axial 3D T1-weighted and axial T2-weighted FLAIR14. Post gadolinium-based contrast (0.1 mmol/kg) T1-weighted imaging was performed 8-12 minutes following injection. Key MRI sequence parameters are listed in Supplemental Table 2.
    PET/MRI image analysis was conducted using MIM Software (V7.1, Institution 1) or Siemens syngo.via MM Oncology (VB 50, Institution 2). Volumes of interest (VOIs) were manually placed on the postcontrast T1-weighted MRI over areas of new or enlarging enhancement. The VOI was used to extract PET SUVmax values from co-registered [F18]-Fluciclovine PET static images. VOI placement was performed by a board-certified neuroradiologist at each site blinded to clinical outcomes.
    Clinical classification of each case, as true progression or treatment-related changes, was based on histopathologic confirmation (when available) or serial imaging follow-up over at least 3 months or until death, consistent with the framework outlined in RANO 2.06,15. For patients undergoing resection or biopsy following PET/MRI, biopsy tissue provided for a clinical diagnosis of viable tumor or treatment-related changes as characterized on histopathology by a board-certified neuropathologist. For patients undergoing serial Gd-MRI to establish disease status, lesions that demonstrated continued enlargement or necessitated change in management were classified as true progression. Lesions that remained stable or regressed without therapeutic change were classified as treatment-related changes.
    Patient characteristics were summarized using descriptive statistics. Group differences in SUVmax were evaluated using Mann Whitney U test, a nonparametric test for two independent samples. Demographic and clinical characteristics between institutions were compared using the Mann–Whitney U test for continuous variables and Fisher’s exact test or chi-square test for categorical variables, as appropriate. For patients with multiple imaging timepoints, only the first episode of presumed disease progression was included in the analysis to ensure independence of included scans and avoid correlation between repeated scans. Receiver operating characteristic (ROC) analysis was used to evaluate diagnostic performance, with the area under the curve (AUC) along with 95% confidence intervals derived by bootstrap resampling with 10,000 iterations. Youden’s J statistic was used to identify the optimal SUVmax cutoff for differentiating true tumor progression from treatment-related changes. Additionally, we evaluated the diagnostic performance of the previously published SUVmax threshold of 4.66, as reported in a prospective, histopathologically confirmed GBM cohort by Nabavizadeh et al. 12 and qualitatively compared its performance within our optimal cohort-specific threshold to assess consistency and generalizability across studies. A p-value less than .05 was considered statistically significant. Statistical analyses were performed using GraphPad Prism (Version 10.6.0, GraphPad Software, La Jolla, CA), Statistics Kingdom (Version August - November 2025, Statistics Calculators, Melborune, Australia) 16, and Stata/SE 16.1 (StataCorp LLC, college Station, TX). Pre-planned sample size justification was not performed.

    RESULTS

    All retrospectively identified patients with presumed GBM disease progression with [F18]-Fluciclovine PET/MRI were included in this cohort. In total, 36 patients were identified (Table 1). Seventeen scans were performed at Institution 1 and 19 at Institution 2. One patient at each institution had two separate episodes of presumed disease progression, but only the first was included in the analysis. Twenty-two PET/MRI examinations were classified as true tumor progression and 14 were classified as treatment-related changes, based on histopathology or radiographic and clinical follow-up. The follow-up time to establish diagnosis was significantly shorter at Institution 1 (P= .01; Table 1). Otherwise, clinical and demographic characteristics, including age, sex, MGMT promoter methylation status, number of prior therapies, proportion of patients who received Bevacizumab or other therapies, time from completion of radiotherapy to PET did not differ significantly between the two institutions (Table 1). The minimum follow up time after [F18]-Fluciclovine PET/MRI imaging to establish diagnosis within our cohort for patients without histological diagnosis of disease status was 0.6 months as result of subsequent death. However, length of follow up time did not preclude a clinical diagnosis of either true tumor progression or treatment-related changes.
    Lesions classified as true progression demonstrated significantly higher SUVmax values compared to those identified as treatment-related changes (p < .01; Figure 1). Figure 2 illustrates representative PET/MRI images from cases of both true progression and treatment-related changes (1 patient from each institution). Median SUVmax values of true progression (P= .02 and treatment-related changes at Institution 1 were overall significantly higher than Institution 2 (P= .03); Table 2).
    ROC analysis revealed SUVmax had excellent diagnostic performance in distinguishing true progression from treatment-related changes, with an AUC of 0.90 (95% CI: 0.79 - 0.98). The optimal SUVmax threshold for this combined 2-institution cohort was 5.7, which yielded a sensitivity of 0.86 (95% CI: 0.70–0.99) and specificity of 0.86 (95% CI: 0.64–0.99) (Figure 3). A stratified analysis by institution demonstrated similar diagnostic performance (Table 3, Supplementary Table S3). The diagnostic performance of the previously published SUVmax threshold from Nabavizadeh et al. was evaluated in our combined 2-institution cohort. This threshold of 4.66 yielded similar performance with AUC of 0.90 (95% CI 0.79–0.98), sensitivity of 0.91 (95% CI: 0.71–0.99), and specificity of 0.71 (95% CI: 0.42–0.92). A subgroup of the 11 patients with histopathological confirmation of disease status (N= 6 true progression and N= 5 treatment related changes) demonstrated a similar diagnostic performance with an AUC of 0.87 (95% CI 0.60–1.00), sensitivity of 0.67 (95% CI: 0.29–0.96), and specificity of 1.0 (95% CI: 0.48–1.00) using the optimal SUVmax threshold of 5.7.
    Nine patients (24%) had received bevacizumab prior to PET. Overall diagnostic accuracy did not differ between patients with and without prior bevacizumab exposure (89% vs 86%, Fisher’s exact p = 1.0). Likewise, no significant difference was observed in SUVmax values between patients with and without prior bevacizumab exposure, irrespective of outcome (P >.37). Within the bevacizumab-treated subgroup (N= 9), SUVmax values trended higher in progression (N = 6) compared to treatment-related change (N= 3), with a SUVmax 7.35 (6.40 - 8.82) vs 3.20 (2.80 - 3.50), however this difference did not reach statistical significance (p = 0.10), likely due to small sample size. In the non-bevacizumab cohort (N= 27), the separation between progression (N = 17) and treatment-related change (N = 10) was robust (9.27 (5.83 - 12.23) vs 4.12 (1.7 - 5.13), p<0.001). Mean and standard deviation for the overall cohort and subgroups SUVmax values are provided in Supplementary Table 4. SUVmax values were not significantly different when stratified by other therapies received prior to [F18]-Fluciclovine PET/MRI (bevacizumab, tumor treatment fields, pembrolizumab, or lomustine, Table 1).

    DISCUSSION

    In this retrospective, multi-institutional cohort study, we investigated the real-world diagnostic performance of [F18]-Fluciclovine PET/MRI for differentiating true tumor progression from treatment-related changes in patients with clinically presumed GBM progression. Our results suggest that SUVmax is significantly elevated in patients with true progression compared to those with treatment-related changes, and that a SUVmax threshold can reliably discriminate between these disease processes with high diagnostic accuracy. Furthermore, SUVmax performed as a robust clinical metric, supporting its applicability in real-world, multi-center clinical settings as a simple, threshold-based approach to facilitate clinical decision-making. Taken together, these findings suggest that [F18]-Fluciclovine PET/MRI offers clinically valuable, biologically specific information to aid in response assessment after standard-of-care CRT. With continued clinical validation in larger, prospective cohorts, [F18]-Fluciclovine PET/MRI could become a valuable diagnostic tool capable of complementing Gd-MRI for evaluating presumed disease progression in patients with GBM.
    Our study suggests that [F18]-Fluciclovine SUVmax accurately differentiates true GBM progression from treatment-related changes, with an AUC of 0.90 and optimal diagnostic threshold of 5.7. These results are consistent with the prospective findings by Nabavizadeh et al., who reported a SUVmax threshold of 4.66 with high diagnostic accuracy (AUC = 0.86) 12. Our ability to replicate their performance metrics in a real-world setting across two academic institutions, including acquisition parameters and analytical software packages, supports the robustness of [F18]-Fluciclovine SUVmax as a clinically prudent biomarker under heterogeneous imaging conditions. Although prior amino acid PET studies have explored ratios such as tumor to background ratio (TBR) or alternative metrics such as SUVpeak, we focused on SUVmax, a metric that has demonstrated excellent diagnostic performance for [F18]-Fluciclovine in GBM, particularly in multi-institutional settings where acquisition protocols vary. Importantly, the close concordance of threshold values across studies suggests that a standardized cutoff may be feasible for broader clinical implementation, reducing variability and interpretation bias.
    Notably, while the two institutions differed in their absolute SUV distributions and optimal cutoffs (Institution 1: 8.64; Institution 2: 5.70), diagnostic accuracy remained consistently high at both sites (AUC 0.87–0.96). This finding highlights that inter-site technical or biological factors may shift absolute SUV, while the discriminatory capacity of [F18]-Fluciclovine PET remains preserved. The robustness of AUC across centers reinforces the generalizability of [F18]-Fluciclovine PET across clinical environments.
    Although bevacizumab can alter the imaging appearance of enhancing lesions by reducing vascular permeability6, our data suggest that prior bevacizumab exposure does not substantially diminish the diagnostic performance of [F18]-Fluciclovine PET. While the bevacizumab-treated subgroup was small, we observed a similar separation of SUVmax values between progression and treatment-related change as in the non-bevacizumab cohort, supporting the potential robustness of Fluciclovine PET even in this clinically challenging setting.
    Our findings are comparable to reports using O-(2-[[F18]]fluoroethyl)-L-tyrosine (FET) PET, which is more widely used in Europe and has similarly demonstrated high diagnostic accuracy for GBM progression. In this context, PET RANO 1.0, and its recent update, PET RANO 2.0, have attempted to formalize the integration of amino acid PET imaging into standardized response assessment frameworks, emphasizing the need for reproducible, biologically specific imaging biomarkers to complement conventional MRI3. However, FET studies have reported a relatively wide range of optimal thresholds and diagnostic performance across institutions, with published TBR cutoffs ranging from ~1.9 to 3.7 and specificity varying considerably17–20. By contrast, both our two-institution cohort and the single-institution experience from Nabavizadeh et al. 12 demonstrate highly consistent SUVmax thresholds and diagnostic accuracy for [F18]-Fluciclovine, suggesting greater robustness and generalizability across clinical settings. In either case, the use of static acquisition and clinically prudent SUVmax thresholds makes amino acid PET imaging more readily applicable in routine clinical workflows. Moreover, [F18]-Fluciclovine is FDA-approved and commercially available in the United States, offering logistical advantages for rapid clinical adoption in neuro-oncology practices.
    In addition to confirming diagnostic performance, our study underscores the limitations of existing imaging methods. Conventional Gd-MRI features, as reflected in RANO 2.0 criteria, remain non-specific, particularly in the early post-treatment period. Although RANO 2.0 introduces updated criteria to improve standardization in Gd-MRI based GBM response assessment, Gd-MRI diagnostic accuracy for distinguishing true progression from treatment-related changes remains limited, with reported accuracies ranging from 50–70% depending on timing and imaging context21. As outlined in RANO 2.0, MRI-based assessment remains the clinical standard. Our findings suggest amino acid PET provides a complementary biologically specific marker that may refine response evaluation. DSC-MRI derived CBV is widely used to assess tumor vascularity. However, its diagnostic accuracy for differentiating GBM progression from treatment-related changes is variable, with reported sensitivities and specificities typically ranging from 60–85%2. FDG-PET has historically shown limited diagnostic accuracy for GBM response assessment due to high physiologic glucose uptake in normal gray matter which reduces tumor-to-background contrast, complicating interpretation22. Prior investigations have attempted to address this marked limitation using delayed imaging protocols. Delayed imaging methodology acquires FDG-PET imaging 3–4 hours post-injection and may improve lesion conspicuity by allowing background cortical activity to decline23. However, even with delayed imaging, reported diagnostic accuracy remains variable, with sensitivities and specificities generally in the 60–80% range, limiting its clinical utility compared to amino acid PET tracers24.
    This study seeks to advance the field of neuro-oncologic imaging by providing real-world, multi-institutional, evidence supporting the clinical utility of [F18]-Fluciclovine PET/MRI for GBM response assessment. By demonstrating high diagnostic accuracy across two centers despite modest inter-site SUV shifts, this work demonstrates that [F18]-Fluciclovine PET offers a robust, biologically specific biomarker that can be seamlessly integrated into routine clinical workflows. Although performed at tertiary academic centers with PET/MRI capabilities, all examinations were performed and interpreted within standard clinical practice rather than under a controlled research protocol, reflecting practical real-world diagnostic implementation. Unlike other imaging modalities that require complex kinetic modeling or suffer from limited specificity, [F18]-Fluciclovine PET/MRI enables straightforward, quantitative interpretation using static imaging, lowering the barrier for broader clinical adoption. These findings align with and extend prior prospective work, moving the field closer to establishing standardized, PET-based criteria for post-treatment response assessment in GBM. Future multi-center studies incorporating PET/CT platforms, community practice settings, and cost-effectiveness analyses will be important to confirm our results and address broader community-based implementation strategies.
    The clinical imaging retrospectively assessed in this study was conducted using [F18]-Fluciclovine, which is FDA-approved for imaging suspected recurrent prostate cancer. Its use for brain tumors is off-label; however, both participating academic centers have achieved consistent insurance reimbursement for neuro-oncologic indications, supporting the practical feasibility of implementation in routine clinical practice. In the absence of any amino-acid PET tracers formally approved by the FDA for brain tumor evaluation in the United States, [F18]-Fluciclovine provided a practical and reimbursable option for addressing the diagnostic uncertainty frequently encountered in patients with GBM. Its use in this context underscores the feasibility of incorporating [F18]-Fluciclovine PET in routine neuro-oncology workflows and highlights the unmet need for expanded regulatory approval of dedicated brain tumor amino acid tracers. These findings and implementation experiences are consistent with the recent RANO/EANO consensus recommendations, which emphasize the expanding clinical utility of amino acid PET for glioma evaluation and the importance of establishing harmonized protocols and regulatory pathways. 3
    This study has several limitations. First, the retrospective design introduces potential selection bias, and histopathologic confirmation was not available for all cases. In some patients, true progression or treatment-related changes were inferred from longitudinal imaging and clinical follow-up, which may be imperfect surrogates introducing the possibility of verification bias and optimism in the reported diagnostic performance metrics. Second, the sample size, while larger than prior single institution studies, remains modest, limiting statistical power and subgroup analyses. Third, imaging protocols, though harmonized to the extent possible, varied slightly across institutions in terms of acquisition time window and post-processing software. Moreover, because most patients in our cohort underwent imaging in the intermediate-to-late post-treatment period (median 9 months after completion of chemoradiation), diagnostic performance estimates may not directly extrapolate to the early post-therapy interval (<6 months), when treatment-related change is most prevalent1,25,26. Prior amino acid PET studies have also demonstrated that diagnostic accuracy and optimal thresholds vary according to the post-treatment interval, with the early post-CRT period posing the greatest interpretive challenge27. Finally, we focused on SUVmax within the lesion and did not assess dynamic PET parameters or serial PET RANO response assessment, which may offer additional diagnostic value in future prospective studies.

    CONCLUSIONS

    In conclusion, our retrospective, multi-institutional study demonstrates that [F18]-Fluciclovine PET/MRI, using a SUVmax threshold, can accurately differentiate true tumor progression from treatment-related changes, with high sensitivity and specificity consistent across institutions. These findings support the clinical utility of [F18]-Fluciclovine PET as a biologically specific adjunct to conventional Gd-MRI. This provides an imaging tool that may improve diagnostic confidence for GBM response assessment. Moreover, given that [F18]-Fluciclovine is FDA-approved and reimbursed for other oncologic indications, its established clinical availability facilitates near-term adoption for neuro-oncology practice in the United States.
    RRDr. Rohan Ramakrishna
    Leading Voice

    Dr. Rohan Ramakrishna

    Neurosurgery · Brain & Spinal Tumor
    Weill Cornell Medicine
    rohanramakrishna
    New York City, NY, USA